AXGN · Full Picture

Axogen, Inc. — the full picture

Earnings window · 2026-04-07 to 2026-07-25 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Operating Expense Trends · Operating expenses (SG&A)Priority 70
    -33.3% operating_income (realized)
    Net loss for the three months ended March 31, 2026 was $(19,584), or (31.9)% of revenue
  2. Outstanding Indebtedness · Debt, leverage & refinancingPriority 68
    -24.1% net_income (realized)
    Other expense, net increased $14,579, or 670.9%, to $16,752 for the three months ended March 31, 2026 compared to $2,173 for the three months ended March 31, 2025
  3. Capital Raise and Use of Proceeds · UnclassifiedPriority 67
    +24.1% liability (realized)
    Net cash provided by financing activities increased $57,123 primarily due to net proceeds from the Offering and proceeds from the exercise of stock options, partially offset by cash used for early payoff and termination of the Credit Facility and payments of employee tax withholding on vested stock awards
  4. Liquidity and Cash Position · Liquidity & cash positionPriority 67
    +37.1% cash (realized)
    The increase in cash and investments was primarily due to net proceeds from the Offering of $133,252 and the release of $2,000 of restricted cash under a lease agreement, partially offset by $69,707 used for early payoff and termination of the Credit Facility and payment of annual bonuses during Q1 2026
  5. Gross Margin Drivers · Gross marginPriority 62
    +18.3% operating_income (realized)
    Gross profit for the quarter ended March 31, 2026 increased $11,256 or 32.2% compared to the quarter ended March 31, 2025
  6. Revenue Performance and Mix · Revenue growth & mixPriority 61
    +21.0% revenue (realized)
    Revenues for the quarter ended March 31, 2026 increased $12,897 or 26.6% compared to the quarter ended March 31, 2025
  7. R&D Spend and Clinical Trials · UnclassifiedPriority 59
    qualitative only
    Clinical trial costs and expenses represented approximately 59% of total research and development costs and expenses for the three months ended March 31, 2026
  8. Investing Activities - Purchases · Investments & securitiesPriority 57
    -13.0% cash (realized)
    The unfavorable change in investing cash flows of $17,303 was primarily due to the purchase of $19,000 of investments and an increase in purchases of property and equipment of $2,533 during Q1 2026
  9. Occupancy and Leasing Activity · Demand, orders & backlogPriority 57
    1 forward row(s)
    Operating and finance lease obligations total $30,410 with $3,203 due in 2027-2028, $7,156 due in 2029-2030 and $12,793 due thereafter
  10. Product Launch and Transition · Products & launchesPriority 57
    qualitative only
  11. Revenue Concentration Risk · Customers & concentrationPriority 57
    qualitative only
    The company derives substantially all of its revenues from sales of nerve repair products to customers in the U.S.
  12. Reimbursement and Payer Mix · Compliance & policy costsPriority 54
    1 forward row(s)
    Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement 40% year-over-year to $9 for hospital outpatient procedures

Threads by pillar

Revenue & Demand Priority 84 · 6 threads

Costs & Margins Priority 77 · 2 threads

Capital & Balance Sheet Priority 85 · 5 threads

Strategy & Portfolio Priority 30 · 1 thread

Legal, Regulatory & Policy Priority 63 · 2 threads

Macro & Market Conditions Priority 21 · 1 thread

Unclassified Priority 74 · 2 threads

Expected impact by metric

metricforward netforward grossrealized
net_income——-56.0%
operating_income——-15.0%
liability——+24.1%
revenue——+21.0%
cash——+51.1%
margin——+3.3%